Core Laboratories (CLB) EBIT Margin (2022 - 2026)

Core Laboratories has reported EBIT Margin for 5 years, with the latest figure at 1.55% in Q1 2026.

• For the quarter ending Q1 2026, EBIT Margin fell 202.0% year-over-year to 1.55%; the trailing twelve-month figure through Mar 2026 stood at 1.35% (down 915.0% YoY), and the FY2025 full-year result was 1.83%, down 935.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 1.55%, up from 22.42% in the prior quarter.
• The five-year high for EBIT Margin was 15.56% in Q3 2025, with the low at 24.9% in Q4 2023.
• Historically, EBIT Margin has averaged 5.92% across 5 years, with a median of 11.3% in 2024.
• Annual changes were most pronounced in 2023 — EBIT Margin plunged 3714 bps — and 2024, when it soared 3586 bps.
• Core Laboratories' EBIT Margin stood at 12.24% in 2022, then sank by 303 bps to 24.9% in 2023, then jumped by 144 bps to 10.97% in 2024, then plunged by 304 bps to 22.42% in 2025, then soared by 107 bps to 1.55% in 2026.
• The last three EBIT Margin figures came in at 1.55% (Q1 2026), 22.42% (Q4 2025), and 15.56% (Q3 2025), per Business Quant data.